Global MedTech platform focusing
on high clinical need chronic diseases
Founded in 2021,EverBridge Group is a global diversified medical technology company focusing on high clinical need chronic diseases. Our mission is "Bridging Medtech Innovations from Asia to the World".
Adhering to the core philosophy of "rapid and high quality scaling", EverBridge Group has successfully built an enabling platform that accurately captures global industry trends and market demand to serve customers globally.
By leveraging the strong R&D capability of our state-of-the-art Medical Technology Research Institute,and the technical and manufacturing capability of our"Six Technology Centers",we have successfully executed on our innovative product roadmap.With the support of our unique "The EBS (EverBridge Business System)",a lean management approach,we have also rapidly scaled our business.In the global medical device market,EverBridge Group has won wide recognition and praise from customers globally for its comprehensive product portfolio,excellent product quality,efficient production capacity,and strong marketing and sales network.
EverBridge Group is dedicated to building a bridge fo medical technology innovation by actively developing global connections and communication to accelerate the advancement of medical technology.By collaborating with many outstanding global partners on better innovation and development of medical technology,we have provided cutting-edge,high-quality and affordable medical technology for patients with high-incidence chronic diseases around the world.We look forward to continuing to help patients globally achieve excellent treatment experiences and improved outcomes.
Providing innovative, high-quality, and accessible medical technology solutions to hundreds of millions of chronic disease patients worldwide, is the founding mission of EverBridge Group. We are committed to serving as a bridge for medical technology innovation in Asia and across the globe, enabling patients worldwide to benefit from exceptional treatments.
CEO of EverBridge GroupJay Wang